Evidence map›Paper›PMID 25835550›Full record

ArticlePloS one2015

Mitochondrial vulnerability and increased susceptibility to nutrient-induced cytotoxicity in fibroblasts from leigh syndrome French canadian patients.

Yan Burelle, Chantal Bemeur, Marie-Eve Rivard, Julie Thompson Legault, Gabrielle Boucher, LSFC Consortium, Charles Morin, Lise Coderre, Christine Des Rosiers

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Disruption ofJournal of rare diseases (Berlin, Germany) · 2025
    Article
  4. Article
  5. Disease models of Leigh syndrome: From yeast to organoids.Journal of inherited metabolic disease · 2024
    Review
  6. Article
  7. Article
  8. Review
  9. Expression signature of the Leigh syndrome French-Canadian type.Molecular genetics and metabolism reports · 2022
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. mTORC1 is required for expression of LRPPRC and cytochrome-American journal of physiology. Cell physiology · 2019
    Article
  17. Review
  18. The Mitochondrial Permeability Transition in Mitochondrial Disorders.Oxidative medicine and cellular longevity · 2019
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Yan BurelleFaculty of Pharmacy, Université de Montréal, Montréal, Canada.
Chantal BemeurFaculty of Pharmacy, Université de Montréal, Montréal, Canada.
Marie-Eve RivardMontreal Heart Institute, Montreal, Canada; Department of Nutrition, Faculty of Medicine, Université de Montréal, Montreal, Canada.
Julie Thompson LegaultMontreal Heart Institute, Montreal, Canada; Department of Nutrition, Faculty of Medicine, Université de Montréal, Montreal, Canada.
Gabrielle BoucherMontreal Heart Institute, Montreal, Canada.
LSFC Consortium
Charles MorinDepartment of Pediatrics and Clinical Research Unit, Complexe hospitalier de la Sagamie, Chicoutimi, QC, Canada.
Lise CoderreMontreal Heart Institute, Montreal, Canada; Department of Nutrition, Faculty of Medicine, Université de Montréal, Montreal, Canada; Department of Medicine, Faculty of Medicine, Université de Montréal, Montréal, Canada.
Christine Des RosiersMontreal Heart Institute, Montreal, Canada; Department of Nutrition, Faculty of Medicine, Université de Montréal, Montreal, Canada.
Montreal Heart Institute · CAUniversité de Montréal · CACégep de Chicoutimi · CA

Funding

Canadian Institutes of Health Research
6 · The paper itself

Abstract

Mutations in LRPPRC are responsible for the French Canadian variant of Leigh Syndrome (LSFC), a severe disorder characterized biochemically by a tissue-specific deficiency of cytochrome c oxidase (COX) and clinically by the occurrence of severe and deadly acidotic crises. Factors that precipitate these crises remain unclear. To better understand the physiopathology and identify potential treatments, we performed a comprehensive analysis of mitochondrial function in LSFC and control fibroblasts. Furthermore, we have used this cell-based model to screen for conditions that promote premature cell death in LSFC cells and test the protective effect of ten interventions targeting well-defined aspects of mitochondrial function. We show that, despite maintaining normal ATP levels, LSFC fibroblasts present several mitochondrial functional abnormalities under normal baseline conditions, which likely impair their capacity to respond to stress. This includes mitochondrial network fragmentation, impaired oxidative phosphorylation capacity, lower membrane potential, increased sensitivity to Ca2+-induced permeability transition, but no changes in reactive oxygen species production. We also show that LSFC fibroblasts display enhanced susceptibility to cell death when exposed to palmitate, an effect that is potentiated by high lactate, while high glucose or acidosis alone or in combination were neutral. Furthermore, we demonstrate that compounds that are known to promote flux through the electron transport chain independent of phosphorylation (methylene blue, dinitrophenol), or modulate fatty acid (L-carnitine) or Krebs cycle metabolism (propionate) are protective, while antioxidants (idebenone, N-acetyl cysteine, resveratrol) exacerbate palmitate plus lactate-induced cell death. Collectively, beyond highlighting multiple alterations in mitochondrial function and increased susceptibility to nutrient-induced cytotoxicity in LSFC fibroblasts, these results raise questions about the nature of the diets, particularly excess fat intake, as well as on the use of antioxidants in patients with LSFC and, possibly, other COX defects.

Indexed as

Adenosine TriphosphateAdolescentAdultCalciumCanadaCase-Control StudiesCell Membrane PermeabilityChildFibroblastsHumansLeigh DiseaseMembrane Potential, MitochondrialMitochondriaMutationNeoplasm ProteinsOxidative PhosphorylationAdenosine TriphosphateCalciumLRPPRC protein, humanNeoplasm ProteinsReactive Oxygen SpeciesSuperoxides

Identifiers

PMID25835550
PMCPMC4383560
OpenAlexW2065176101

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.